SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IPIC
IPIC 0.00010000.0%Nov 28 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: WeirdPro Randy who wrote (938)12/14/1997 2:09:00 PM
From: NeuroInvestment  Read Replies (1) of 1359
 
Precisely. My comments about those 'missing' valve patients did not refer to symptomatic patients, it relates to those with detectable anomalies, even if asymptomatic. I would add that the population of Redux users is overweight, more prone to a variety of other medical disorders, and under some type of physician care more often than not (since someone had to write the scrip, in the US or Europe). Thus they would be more likely to have any subclinical anomalies in valvular function picked up via auscultation than the general population. In other words, if there did exist a vast population of asymptomatic but subtly damaged individuals, it should have been noticed, at least to a degree considerably greater than the microscopic proportions noted thus far (i.e. a total of 72 Redux-only patients found to date with valvular anomalies out of the first 12,000,000 Redux-users.) If there is a clinically substantial, causal link with fluramine drugs, that should have emerged regardless of how long it takes for florid symptomatology to display itself. Hence the AIDS analogy is worthless, save for tabloid value. NeuroInvestment
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext